Incidence, management and outcome of women requiring massive transfusion after childbirth in the Netherlands: secondary analysis of a nationwide cohort study between 2004 and 2006

Paul I. Ramler¹,²*, Thomas van den Akker¹, Dacia D. C. A. Henriquez¹,³, Joost J. Zwart⁴ and Jos van Roosmalen¹,⁵

Abstract

Background: Postpartum hemorrhage remains the leading cause of maternal morbidity and mortality worldwide. Few population-based studies have examined the epidemiology of massive transfusion for postpartum hemorrhage. The aim of this study was to determine the incidence, management, and outcomes of women with postpartum hemorrhage who required massive transfusion in the Netherlands between 2004 and 2006.

Methods: Data for all women from a gestational age of 20 weeks onwards who had postpartum hemorrhage requiring eight or more red blood cell concentrates were obtained from a nationwide population-based cohort study including all 98 hospitals with a maternity unit in the Netherlands.

Results: Three hundred twenty-seven women who had postpartum hemorrhage requiring massive transfusion were identified (massive transfusion rate 91 per 100,000 deliveries (95% confidence interval: 81–101)). The median blood loss was 4500 mL (interquartile range 3250–6000 mL) and the median number of red blood cell concentrates transfused was 11 units (interquartile range 9–16 units). Among women receiving massive transfusion, the most common cause of hemorrhage was uterine atony. Eighty-three women (25%) underwent hysterectomy, 227 (69%) were admitted to an intensive care unit, and three women died (case fatality rate 0.9%).

Conclusion: The number of women in the Netherlands who had postpartum hemorrhage treated with massive transfusion was relatively high compared to other comparable settings. Evidence-based uniform management guidelines are necessary.

Keywords: Postpartum hemorrhage, Blood transfusion, Obstetrics, Maternal mortality, Maternal morbidity

Background

Around the globe, postpartum hemorrhage (PPH) continues to be a leading cause of both maternal morbidity and mortality [1, 2]. In the Netherlands, PPH is defined by at least 1000 mL blood loss within 24 h of giving birth. There has been an increase in the incidence of PPH among all births in the Netherlands from 4.1% in 2000 to 6.4% in 2013 [3]. Although case definitions of PPH vary between countries, this rising incidence of PPH is also evident in other high-income countries [4–8]. An explanation for the increasing rates of PPH remains unclear.

In high-income countries, pharmacological, mechanical and surgical methods as well as radiological arterial embolization are available to arrest heavy bleeding. In case of life-threatening PPH, access to and use of sufficient quantities of blood products for transfusion to treat severe anemia and correct clotting disorder are critical [9, 10]. Clinical benefit of blood transfusion in
obstetric hemorrhage was demonstrated in a hypothet-
ical experimental study showing a 6.5-fold increase in
risk of maternal death had red blood cell concentrates
(RBCs) not been available, as is the case in many low-
income settings [11].

Little is known about the management and outcomes
of women who sustain PPH requiring massive transfu-
sion. A recent population-based study from the United
Kingdom (UK) indicated that PPH requiring massive
transfusion was associated with high rates of morbidity
and hysterectomy [12]. While the rate of obstetric trans-
sfusion in the Netherlands has decreased dramatically over
time (from 23% in 2000 to 3.9% in 2013), transfusion rates
in other high-income countries increased [3, 13, 14]. If
rates of massive transfusion in the Netherlands were to
have decreased over time, these data would be important
for informing discussion about best transfusion practices
for PPH management. The objective of our present study
was to determine incidence, causes, management and clin-
cial outcome of women with PPH requiring massive trans-
fusion in the Netherlands.

Methods
To determine incidence, causes, management approaches,
and clinical outcomes of women who had PPH requiring
massive transfusion in the Netherlands, we performed a
secondary analysis of data from the LEMMoN study
(Landelijke studie naar Etnische determinanten van
Maternale Morbiditeit in Nederland) [15].

The LEMMoN study included 358,874 deliveries with
severe acute maternal morbidity that occurred in 98 hos-
pitals with a maternity unit in the Netherlands (100%)
between 1st August 2004 and 1st August 2006. Severe
acute maternal morbidity was categorized into five
groups: intensive care unit (ICU) admission, uterine
rupture, eclampsia/HELLP syndrome, major obstetric
hemorrhage and a miscellaneous group. Major obstetric
hemorrhage was defined as a need for transfusion of
four or more units of erythrocyte concentrate or
embolization or hysterectomy following PPH. Detailed
information about study design and data collection were
described previously [15]. For this specific study, we
selected women from the LEMMoN cohort who were
classified as ‘major obstetric hemorrhage’; had a gesta-
tional age of at least 20 weeks and received massive
transfusion, defined as eight or more red blood cell
concentrates within the first 24 h after delivery.

We recorded maternal characteristics (age, body mass
index (BMI), geographical ethnic origin (the Netherlands,
other European Countries or non-Western immigrants,
subdivided into Middle East/North Africa, sub-Saharan
Africa, South America and Far East), parity, previous
experienced PPH and previous cesarean section), preg-
nancy characteristics (gestational age, mode of delivery,
induction of labour, multiple pregnancy and preeclampsia)
and specific data on postpartum hemorrhage (amount of
blood loss, number of red blood cell concentrates transfu-
sed, hemoglobin levels at onset of bleeding, after bleeding
and at day of discharge). Maternal and pregnancy
characteristics of women in this study were compared to
the general pregnant population of the Netherlands, ob-
tained from Statistics Netherlands (CBS) and National
Perinatal Database (LVR-2). Incidence figures in LVR-2
were multiplied by 59/100 to also represent all deliveries
under primary care (41% in 2002) [16, 17].

Since postpartum hemorrhage is often the result of con-
current causes, we re-examined all cases of massive trans-
fusion within the LEMMoN-cohort and registered up to
three causes of PPH requiring massive transfusion for
each individual case. Only those causes that contributed
significantly to the hemorrhage were registered. These
causes were noted as uterine atony, uterine rupture, iat-
rogenic during/after cesarean section, placental abnor-
malities (including retained placenta, placental remnant,
placenta previa, abnormally invasive placenta and placen-
tal abruption (resulting in continuous hemorrhage in the
postpartum period), laceration of vagina and/or cervix,
primary clotting disorder with or without antenatal fluid
embolism, rupture of the uterine artery, rupture of the
liver capsule and uterine inversion. Causes of hemorrhage
were analyzed by mode of birth (spontaneous vaginal de-
livery, instrumental vaginal delivery, elective cesarean
section, emergency cesarean section and termination of
pregnancy) and number of red blood cell concentrates
transfused (‘moderate’ (8–12 units), ‘high’ (13–20 units)
and ‘immense’ (>20 units). The cut-off points for the
number of red blood cell concentrates transfused were
identical to those described by Green et al. [12].

Management of postpartum hemorrhage requiring
massive transfusion was divided into uterotonic agents
(oxytocin, prostaglandin F2α, ergometrine, misoprostol),
non-uterotonic drugs (tranexamic acid), mechanical in-
terventions (intrauterine balloon, intrauterine packing
and intra-abdominal packing), surgical interventions
removal of the placenta not performed during cesarean
section, laparotomy, re-laparotomy, B-Lynch suture,
uterine artery ligation and hysterectomy) and uterine
artery embolization. Outcome of women was determined
by need for hysterectomy, length of hospitalization, ICU ad-
mission, morbidity, maternal deaths and case fatality rate.

Statistical analyses were performed using IBM SPSS
Statistics (version 22.0; SPSS Inc., Chicago, IL). Discrete
data were summarized as frequencies and percentages,
while continuous data were noted as medians with an
interquartile range (IQR) expressed as the 25th and 75th
percentiles. Women with a missing value for a specific
parameter were excluded when calculating the rate for
that variable.
Results
During the study period, 358,874 deliveries took place in the Netherlands; 336 women sustained PPH and were given eight or more units of red blood cell concentrates. Of these women, nine were excluded due to a gestational age below 20 weeks, leaving 327 women for analysis. Incidence of massive transfusion due to PPH was 91 per 100,000 deliveries (95% confidence interval [95% CI]: 81–101). Clinical and demographic baseline characteristics for women are presented in Table 1 and characteristics of the pregnancies in Table 2. The median (IQR) age, BMI and gestational age were 33 years (30–36 years), 23 kg/m² (21–26 kg/m²) and 38 weeks (37–41 weeks), respectively.

Characteristics of postpartum hemorrhage requiring massive transfusion
The median (IQR) estimated blood loss was 4500 mL (3250–6000 mL), resulting in a median (IQR) hemoglobin drop from 11.6 g/dL (10.8–12.41 g/dL; data missing for 60 women) before hemorrhage to 5.96 g/dL (5–6.77 g/dL; data missing for 34 women) after hemorrhage. The median (IQR, range) number of red blood cell concentrates transfused was 11 (9–16, 8–52) (see Additional file 1 for distribution).

The most common cause of PPH requiring massive transfusion was uterine atony, followed by retained placenta and placenta previa (Table 3). For 117 women (36%), two causes were registered and for 12 women (4%) three. The commonest combinations for women with two causes were uterine atony with retained placenta (N = 28), uterine atony with placental remnant (N = 21) and uterine atony with cervical laceration (N = 10). For women with three causes, the most frequent combination was uterine atony with placental remnant and cervical laceration (N = 3). For nine women, no cause could be established. The 22 causes in the ‘other’ category in Table 3 were primary clotting disorder without amniotic fluid embolism (N = 7), uterine artery rupture (N = 6), live capsule rupture (N = 4), clotting disorder due to amniotic fluid embolism (N = 4) and uterine inversion (N = 1). Massive transfusion occurred during normal working hours (between 0800 and 1600 on a weekday) for 196 (65%) women; data were missing for 25 women. The onset of hemorrhage occurred at home for 52 (16%) women; data were missing for 7 women.

Table 1 Characteristics of the women

|                      | N (%) | General pregnant population in the Netherlands (%) |
|----------------------|-------|-----------------------------------------------|
| Age (years)          |       |                                               |
| 20–34                | 208 (63) | (75.3)                                        |
| 35–39                | 94 (29)  | (21.3)                                        |
| ≥ 40                 | 25 (8)   | (3.4)                                         |
| BMI (kg/m²)          |       |                                               |
| < 18.5               | 15 (5)   | (3.1)                                         |
| 18.5–24.9            | 137 (42) | (65.2)                                        |
| 25.0–29.9            | 39 (12)  | (21.9)                                        |
| ≥ 30                 | 24 (7)   | (9.8)                                         |
| Unknown              | 112 (34) | –                                             |
| Geographical ethnic origin |   |                                               |
| The Netherlands     | 223 (68) | N/A                                           |
| Other European Countries | 7 (2) | N/A                                           |
| Non-Western immigrants; | 70 (22) | (16.8)                                        |
| Middle East/North Africa | 28 (7) | N/A                                           |
| Sub-Saharan Africa  | 17 (5)   | N/A                                           |
| South America       | 16 (5)   | N/A                                           |
| Far East            | 9 (3)    | N/A                                           |
| Unknown             | 27 (8)   | –                                             |
| Parity              |       |                                               |
| 0                   | 158 (48.3) | (45.2)                                        |
| 1–2                 | 145 (44.3) | (49.8)                                        |
| ≥ 3                 | 24 (7.3)  | (5.0)                                         |
| Previous postpartum hemorrhage | 40 (12) | N/A                                           |
| Previous cesarean section | 66 (20) | (6.0)                                         |

N/A data not available
*National reference values from Statistics Netherlands (exact study period) [16]

Table 2 Characteristics of pregnancy and birth

|                      | N (%) | General pregnant population in the Netherlands (%) |
|----------------------|-------|-----------------------------------------------|
| Gestational age      |       |                                               |
| Preterm (<37 weeks); | 86 (26) | (5.8)                                        |
| 20–24 weeks          | 6 (2)  | N/A                                           |
| 24–32 weeks          | 18 (5) | N/A                                           |
| 32–37 weeks          | 62 (19) | N/A                                           |
| Full Term            | 241 (74) | (94.2)                                        |
| Mode of delivery     |       |                                               |
| Vaginal              | 131 (40) | (78.4)                                        |
| Instrumental         | 43 (13) | (8.6)                                         |
| Cesarean Section;    | 151 (46) | (13.0)                                        |
| Elective             | 46 (14) | N/A                                           |
| Emergency            | 105 (32) | N/A                                           |
| Induction of labour  | 100 (31) | (12.5)                                        |
| Multiple pregnancy   | 37 (11)  | (1.7)                                         |
| Preeclampsia during pregnancy | 54 (17) | (4) [19]                                       |

N/A data not available
*National reference values from Statistics Netherlands (exact study period) [16]

National reference values from the Netherlands Perinatal Registry (LVR-2, 2005) [17]
*In case of multiple births were the mode of delivery differed between the neonates, the mode of delivery refers to the most invasive mode
Table 3: Causes of PPH cases requiring massive transfusion

| Cause                                | N   | (%) |
|--------------------------------------|-----|-----|
| Uterine atony                        | 179 | (55)|
| Placenta abnormalities; Retained     | 173 | (53)|
| Previa                               | 54  | (17)|
| Abnormally invasive placenta         | 37  | (11)|
| Remnant                              | 32  | (10)|
| Abruption                            | 30  | (9)|
| Laceration; Vagina                   | 20  | (6)|
| Cervix                               | 17  | (5)|
| Uterine rupture                      | 23  | (7)|
| Iatrogenic during/after cesarean     | 11  | (3)|
| Other                                | 22  | (7)|
| Unknown                              | 9   | (3)|

*Up to three causes per case could be included

Table 4: Top 3 causes categorized by mode of birth

| Mode of Birth                  | N   | (%) |
|--------------------------------|-----|-----|
| Vaginal birth (N = 131)        |     |     |
| 1. Uterine atony               | 84  | (64)|
| 2. Retained placenta           | 40  | (31)|
| 3. Placental remnant           | 20  | (15)|
| Instrumental vaginal birth (N = 43) |     |     |
| 1. Uterine atony               | 26  | (60)|
| 2. Retained placenta           | 14  | (33)|
| 3. Placental remnant           | 6   | (14)|
| Elective cesarean section (N = 46) |     |     |
| 1. Placenta previa             | 24  | (52)|
| 2. Uterine atony               | 17  | (37)|
| 3. Abnormally invasive placenta| 13  | (28)|
| Emergency cesarean section (N = 105) |     |     |
| 1. Uterine atony               | 51  | (49)|
| 2. Uterine rupture             | 13  | (12)|
| 3. Iatrogenic during/after cesarean | 9   | (9)|
| Termination of pregnancy (n = 2) |     |     |
| 1. Uterine atony               | 1   | (50)|
| 2. Uterine rupture             | 1   | (50)|

*Up to three causes could be included

Management of postpartum hemorrhage requiring massive transfusion

Oxytocin (84%) was the most frequently administered uterotonic agent (prophylactic oxytocin excluded), followed by prostaglandin F2α (70%) and ergometrine (18%) (Table 5). No data regarding which uterotonic agent was administered as first line treatment were retrievable, but of 284 women who received oxytocin, 210 (74%) were given prostaglandin F2α thereafter. Eleven women who had uterine atony received no oxytocin. Instead, these women received prostaglandin F2α and one woman was supplemented with tranexamic acid.

Laparotomy was performed following 42/174 (24%) vaginal deliveries and 82/151 (54%) cesarean sections. Repeat laparotomy was necessary in 10/42 (24%) and 20/82 (24%) respectively. Of all 327 women, 83 (25%) underwent hysterectomy to control bleeding with highest rates in women who sustained uterine rupture (N = 14/20, 70%) or any form of abnormal placentation (N = 21/32, 66%).

Outcome of women requiring massive transfusion

The median (IQR) length of hospitalization was 9 days (6–13 days; data missing for 14 women) and 227 women (69%) required ICU admission. The median (IQR) hemoglobin on the day of discharge was 10.15 g/dL (9.02–11.44 g/dL; data missing for 53 women). One-hundred-and-twenty-one (37%) women experienced some kind of morbidity, of whom 40 (33%) developed respiratory failure and 13 (11%) experienced renal insufficiency. Other complications were paralytic ileus (N = 11), heart failure (N = 7), Sheehan syndrome (N = 6) and cerebral venous sinus thrombosis (N = 2). Maternal death occurred in three women due to hypovolemic shock, ventricular fibrillation and massive pulmonary embolism; case fatality rate of postpartum hemorrhage requiring massive transfusion was 1 in 109 (0.9%).

Discussion

Between 2004 and 2006, the incidence of postpartum hemorrhage treated with massive transfusion was notably high in the Netherlands (91 per 100,000 deliveries). This is four times the incidence reported for the United Kingdom between 2012 and 2013 (23 per 100,000 deliveries), and one-and-a-half times the incidence reported for the state of New York between 1998 and 2007 (60 per 100,000 deliveries) [12, 18]. We found that the leading cause of PPH with massive transfusion was uterine atony. One quarter of all women receiving massive transfusion underwent hysterectomy to control bleeding.
The difference in the incidence of massive transfusion due to PPH between the Netherlands and the UK is remarkable. Whereas incidence of major obstetric hemorrhage has differed between various countries as a result of varying inclusion criteria [15, 19, 20], our study applied the same inclusion criteria for massive transfusion described by Green et al. [12].

The difference in incidence between the Netherlands and the state of New York is also of note, particularly since Mhyre et al. [18] used a higher threshold for the number of red blood cell concentrates transfused to define massive transfusion (≥ 10 units) and included both antepartum and postpartum hemorrhage.

A distinct difference between the national guidelines for the management of PPH between the Netherlands (Dutch Society of Obstetrics and Gynaecology (NVOG)) and the United Kingdom (Royal College of Obstetricians and Gynaecology (RCOG)) is that the RCOG specifically recommends that ‘surgical interventions should be initiated sooner rather than later’. Both guidelines are inconclusive concerning the administration of blood products; NVOG (see Additional file 2 for a summary of the NVOG PPH guideline represented as a chart [9]) recommends not to deviate from the local guidelines of the hospital, while RCOG states that the decision to provide blood transfusion ‘should be based on both clinical and hematological assessment’ [9, 10, 21]. Furthermore, it is noteworthy that the median estimated blood loss in the study from Green et al. was 6 L (4.5–8.0 L) versus 4.5 L (3.3–6 L) in our cohort, whilst the massive transfusion rate was four times higher in the Netherlands [12]. This may suggest that the difference in transfusion rate is due to differences in transfusion policy, which would emphasize the need for uniform guidelines [22].

During the study period, there were 358,874 deliveries in the Netherlands and 145,703 deliveries (40.6%) were under the responsibility of a primary care giver, making the risk of massive transfusion due to PPH 13 per 100,000 deliveries in midwifery care. Comparison of women requiring massive transfusion due to PPH with the general pregnant population in the Netherlands showed that women requiring massive transfusion had a multiple pregnancy in 11% of all cases versus 1.7% in the general population [16], suffered from preeclampsia in 17% of all cases versus 4% in the general population [23], had labour induced in 31% of all cases versus 12.5% in the general population [17], had a preterm delivery in 26% of all cases versus 5.8% in the general population [17] and delivered by cesarean section in 46% in all cases versus 13% in the general population [17]. These characteristics are known risk factors of PPH and highlight that the management of postpartum hemorrhage should not only be focused on treatment, but on prevention as well [24, 25].

Uterine atony was the most frequent cause of postpartum hemorrhage as is consistent with the literature [12, 26, 27]. Atony was also the commonest cause of PPH in home deliveries [28]. In elective cesarean sections the leading cause of massive transfusion due to PPH was placenta previa. Green et al. reported placenta accreta as the most frequent cause of PPH in women delivering by elective cesarean section, while Dupont et al.

| Table 5 Distribution of obstetric interventions by cause; expressed as percentages |
|---------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
|                                | Atony (N = 179) | Rupture (N = 20) | Previa (N = 37) | AIPb (N = 32) | Abruption (N = 20) | Retained (N = 54) | Total (N = 327) |
| Oxytocin                        | 94          | 70          | 87          | 91          | 70          | 87          | 84          |
| Prostaglandin F2α               | 87          | 50          | 54          | 72          | 55          | 85          | 70          |
| Tranexamic acid                 | 33          | 5           | 19          | 13          | 5           | 19          | 22          |
| Ergometrine                     | 23          | 15          | 14          | 19          | 20          | 28          | 18          |
| Misoprostol                     | 16          | 5           | 3           | 3           | 20          | 6           | 11          |
| Removal of placentaab           | 31          | 15          | 11          | 41          | 15          | 100         | 29          |
| Intrauterine balloon            | 32          | 10          | 14          | 28          | 5           | 19          | 23          |
| Intrauterine packing            | 30          | 15          | 22          | 22          | 5           | 22          | 21          |
| Intra-abdominal packing         | 6           | 30          | 0           | 3           | 0           | 4           | 7           |
| Uterine artery ligation         | 6           | 5           | 8           | 3           | 5           | 4           | 5           |
| Uterine artery embolization     | 29          | 10          | 19          | 19          | 5           | 22          | 22          |
| Laparotomy                      | 36          | 70          | 51          | 63          | 15          | 13          | 38          |
| Re-laparotomy                   | 8           | 30          | 5           | 0           | 0           | 6           | 9           |
| B-Lynch suture                  | 5           | 0           | 3           | 3           | 10          | 0           | 2           |
| Hysterectomy                    | 27          | 70          | 38          | 66          | 5           | 9           | 25          |

aAbnormally invasive placenta | bIncluded only removal of the placenta (or placental remnant) not performed during cesarean section

Ramler et al. BMC Pregnancy and Childbirth (2017) 17:197 Page 5 of 8
in France found that uterine atony remained the main cause of PPH regardless of mode of birth [12, 27]. The higher percentage of laparotomies performed after cesarean section is consistent with previous findings from the LEMMoN-cohort that the risk of postpartum laparotomy was more than 16 times higher in women who delivered by cesarean section compared to those who delivered vaginally [29].

As a last resort to arrest heavy bleeding, a quarter of all women underwent hysterectomy. This percentage is considerably lower than reported by Green et al. for the UK, where the overall rate of hysterectomy was 45%. A possible explanation for this difference could be the lower rates of previous cesarean deliveries; 66/327 (20%) in our study versus 73/181 (40%) in the [12]. Two studies showed that the risk of peripartum hysterectomy increased with the number of previous cesarean deliveries [30, 31]. Another contributing factor could be the higher rate of embolization in our study, 72/327 (22%) versus 29/181 (16%) in the UK, and thereby preventing the need for hysterectomy. Furthermore, uterine rupture or an abnormally invasive placenta had the highest rates of hysterectomy compared to other causes. This is coherent with the recommendation of the Dutch Society of Obstetrics and Gynaecology guideline that states that hysterectomy should not be postponed if the cause of hemorrhage is related to a placenta accreta or ruptured uterus [10].

The maternal mortality rate of massive transfusion due to PPH in our study was low with 0.84 deaths per 100,000 maternities. This is comparable with the maternal mortality rate of PPH in the Netherlands reported by Schutte et al. between 1993 and 2005 (0.7 deaths per 100,000 maternities) [32]. Nearly three-quarters of women who received massive transfusion were admitted to an ICU, and about one-third experienced morbidity. This high rate of morbidity is consistent with other studies [12, 26]. The rate of morbidity may be higher in low-income settings where not all treatment modalities are available or for Jehovah’s witnesses who refuse blood products [3, 15, 33].

A key strength is that our results were based on a nationwide cohort compromising all hospitals in the Netherlands with a maternity unit. Considering that PPH cases requiring massive transfusion must have been managed in one of these units, our results are population-based. Furthermore, our results are directly comparable to those of Green et al. who used the same definition for massive transfusion in their analysis of a UK cohort [12].

However, number of red blood cell concentrates as definition for massive transfusion remains an indicator with shortcomings as well, since it can be influenced by other factors, such as obstetrician’s decision-making. We also acknowledge that our data are from 2004 to 2006 and may not reflect the current situation. Since the incidence of PPH increased significantly throughout the years in many countries, but the incidence of obstetric blood transfusion in the Netherlands decreased [3], it is possible that the incidence of massive transfusion due to PPH may have reduced in recent years, but this is subject of further assessment. There may have been inclusion bias, since identification and management of cases may differ between obstetricians and hospitals. Underreporting is a concern, however, we have previously observed that there is a negative correlation between the rate of underreporting and the number of red blood cell concentrates transfused [34]. Therefore, we would expect a low rate of underreporting. The considerable number of women without a known Hb-level at discharge is likely due to missing data, as a result of the design of the LEMMoN-database that did not specifically include Hb-level at discharge.

Nevertheless, this study makes clear that the incidence of PPH requiring massive transfusion was high in the Netherlands at that time compared to other countries and further research of contemporary obstetric cohorts is needed to allow for more up to date international comparisons of rates of transfusion and hemorrhage-related morbidity. Networks such as the International Network of Obstetric Surveillance Systems (INOSS) could facilitate such studies [35].

Conclusions
This study adds to the understanding of causes, management and outcomes of women with postpartum hemorrhage requiring massive transfusion and our results show that massive transfusion due to PPH is complicated by high rates of morbidity and a considerable risk of hysterectomy. The incidence of massive transfusion due to PPH appears higher in the Netherlands compared to the UK and the US. Increased vigilance for women at risk or in early stages of postpartum hemorrhage in the Netherlands is needed, while avoiding unnecessary over-transfusion. Specific reasons for the higher incidence will have to be studied in order to improve care accordingly. Our results show the importance of population-wide studies of severe maternal outcome in general, and those comparing rates of transfusion and outcomes for women with severe postpartum hemorrhage in particular.

Additional files

Additional file 1: Distribution of the number of red blood cells concentrates transfused (PDF 142 kb).

Additional file 2: Summary chart of the Dutch Society of Obstetricians and Gynecology PPH guideline [9] (PDF 85 kb).
Acknowledgements
We would like to thank all the 98 local hospital coordinators for participating in the LEMoNoN study.

Funding
No funding was received for this study.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available, since these are owned by Leiden University Medical Centre (LUMC). Subsets are available from the corresponding author on request.

Authors’ contributions
PR and JvR designed the study. PR carried out the analysis and wrote the first draft. JvR, TvdA, JZ, DH all contributed significantly to data analysis, interpretation, and writing of the manuscript. All authors have read and approved the final version of this manuscript.

Competing interests
JvR and TvdA are part of the editorial board of the journal: JvR as a section editor and TvdA as an associate editor.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The LEMoNoN study was approved by the Medical Ethics Committee of Leiden University Medical Centre (P04-020; March 8, 2004). The ethical approval covers the current study as well.

Consent for publication
Not applicable.

Acknowledgements
We would like to thank all the 98 local hospital coordinators for participating in the LEMoNoN study.

Funding
No funding was received for this study.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available, since these are owned by Leiden University Medical Centre (LUMC). Subsets are available from the corresponding author on request.

Authors’ contributions
PR and JvR designed the study. PR carried out the analysis and wrote the first draft. JvR, TvdA, JZ, DH all contributed significantly to data analysis, interpretation, and writing of the manuscript. All authors have read and approved the final version of this manuscript.

Competing interests
JvR and TvdA are part of the editorial board of the journal: JvR as a section editor and TvdA as an associate editor.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The LEMoNoN study was approved by the Medical Ethics Committee of Leiden University Medical Centre (P04-020; March 8, 2004). The ethical approval covers the current study as well.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Obstetrics, Leiden University Medical Center, Leiden, the Netherlands. 2Department of Obstetrics and Gynaecology, Haaglanden Medical Center, The Hague, the Netherlands. 3Department of Obstetrics and Gynaecology, Haga Hospital, The Hague, the Netherlands. 4Department of Obstetrics and Gynaecology, Deventer Hospital, Deventer, the Netherlands. 5Athena Institute, VU University, Amsterdam, the Netherlands.

Received: 1 March 2017 Accepted: 13 June 2017
Published online: 19 June 2017

References
1. Say L, Chou D, Gemmill A, et al. Global causes of maternal deaths: a WHO systematic analysis. Lancet Glob Health. 2014;2:e323–33.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;267:1066–74.
3. van Stralen G, von Schmidt auf Altenstadt JF, Bloemenkamp KW, van Roosmalen J, Hulkkonen CPM. Increasing incidence of postpartum haemorrhage: the Dutch piece of the puzzle. Acta Obstet Gynecol Scand 2016;95:1104-1110.
4. Ford JB, Roberts CL, Simpson JM, Vaughan J, Cameron CA. Increased postpartum haemorrhage rates in Australia. Int J Gynecol Obstet. 2007;98:237–43.
5. Cameron CA, Roberts CL, Oliffe EC, Ford JB, Fischer WE. Trends in postpartum haemorrhage. Aust N Z J Public Health. 2006;30:151–6.
6. Callaghan WM, Kulina EV, Berg CJ. Trends in postpartum haemorrhage. United States, 1994-2006. Am J Obstet Gynecol. 2010;202:535.e1–6.
7. Joseph KS, Rouleau J, Kramer MS, Young DC, Liston RM, Baskett TF. For the Maternal Health Study Group of the Canadian Perinatal Surveillance System. Investigation of an increase in postpartum hemorrhage in Canada. BJOG. 2007;114:751–9.
8. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high risk countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9:55.
9. Nederlandse Vereniging voor Obstetrie en Gynaecologie. Haemorrhagia postpartum (versie 2.0). Utrecht: NVOG; 2006. http://www.nvog-documenten.nl/richtlijn/doc/download.php?id=528. Accessed 12 Dec 2016.
10. Nederlandse Vereniging voor Obstetrie en Gynaecologie. NVOG-richtlijn Haemorrhagia postpartum (HPP). Arnhem: NVOG; 2013. http://www.nvog-documenten.nl/uploaded/docs/NVOG%20richtlijn%20%20HPP%202014-11-2013%20herzien%202015he.pdf. Accesses 12 Dec 2016.
11. Hendriks J, Zwart JI, Briet E, Brand A, van Roosmalen J. The clinical benefit of blood transfusion: a hypothetical experiment based on a nationwide survey of severe maternal morbidity. Vox Sang. 2013;104:234–9.
12. Green L, Knight M, Seeley FM, et al. The epidemiology and outcomes of women with postpartum haemorrhage requiring massive transfusion with eight or more units of red cells: a national cross-sectional study. BJOG. 2015. DOI: 10.1111/1471-0528.13831.
13. Patterson JA, Roberts CL, Bowyer JR, et al. Blood transfusion during pregnancy, birth, and the postnatal period. Obstet Gynecol. 2014;123(1):126–33.
14. Callaghan WM, Kulina EV, Berg CJ. Trends in postpartum hemorrhage. United States, 1994-2006. Am J Obstet Gynecol. 2010;202:535.e1–6.
15. Zwart JI, Richters JM, Ory F, de Vries II, Bloemenkamp KW, van Roosmalen J. Severe maternal morbidity during pregnancy, delivery and puerperium in the Netherlands: a nationwide population-based study of 371,000 pregnancies. BJOG. 2008;115:842–50.
16. Statistics Netherlands (CBS). Statline, Central Bureau of Statistics. http://www.cbs.nl/en-gb. (2007). Accessed on 2 Oct 2007.
17. The Netherlands Perinatal Registry, Perinatal Care in The Netherlands. Bilthoven, the Netherlands: the Netherlands Perinatal Registry. 2005;2007.
18. Mhyre JM, Shilkrut A, Kulina EV, et al. Massive blood transfusion during hospitalization for delivery in New York State, 1998-2007. Obstet Gynecol. 2013;122(6):1288–94.
19. Mart L, Lennox C, McFadyen AK. Quantifying severe maternal morbidity in Scotland: a continuous audit since 2003. Curr Opin Anesthesiol. 2014; 27:275–81.
20. Waterstone M, Bewley S, Wolfe C. Incidence and predictors of severe obstetric morbidity: case-control study. BMJ. 2001;322:1089–93.
21. Mayrides E, Allard S, Chandranarain E, et al. Prevention and management of postpartum haemorrhage: green-top guideline no. 52. BJOG. 2017;124(5):e406–49.
22. Shaylor R, Weiniger CF, Austin N, et al. National and international guidelines for patient blood management in obstetrics: a qualitative review. Anesth Analg. 2017;124(1):216–32.
23. Moi BW, Roberts CT, Thangaratnam S, Magee LA, De Groot CJ, Hoffmeyer GJ. Pre-eclampsia. Lancet. 2016;387(10029):999–1011.
24. Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clin Obstet Gynecol. 2010;53(1):47–56.
25. Bonnet MP, Basso O, Bouvier-Colle MH, et al. Postpartum haemorrhage in Canada and France: a population-based comparison. PLoS One. 2013;8(6):e66882.
26. Bateman BT, Berman MF, Riley LE, Leffert LR. The epidemiology of postpartum hemorrhage in a large, nationwide sample of deliveries. Anesth Analg. 2010;110:388–73.
27. Dupont C, Rudzio RC, Cortet M, et al. Frequency, causes and risk factors of postpartum haemorrhage: a population-based study in 106 French maternity units. J Gynecol Obstet Biol Reprod (Paris). 2014;43(3):244–53.
28. Smit C, Chan KL, Middeldorp JM, van Roosmalen J. Postpartum haemorrhage in midwifery care in The Netherlands: validation of quality indicators for midwifery guidelines. BMC Pregnancy Childbirth. 2014;14:397.
29. Witteveen T, Kallandins A, van den Akker T, Zwart J, Bloemenkamp K, van Roosmalen J. Laparotomy after childbirth: a two-year nationwide cohort study in the Netherlands. Findings have been presented at the 21st FIGO World Congress of Gynaecology and Obstetrics (4-9 October 2015).
30. Submitted for publication.
31. Knight M, Kurinczuk JJ, Spark P, Brocklehurst P. Cesarean delivery and peripartum hysterectomy. Obstet Gynecol. 2008;111:97–105.
31. Bateman BT, Mhyre JM, Callaghan WM, Kuklina EV. Peripartum hysterectomy in the United States: nationwide 14 year experience. Am J Obstet Gynecol. 2012;206(1):63.e1–8.
32. Schutte JM, Steegers EAP, Schuitemaker NWE, et al. The Netherlands maternal mortality committee. rise in maternal mortality in the Netherlands. BJOG. 2010;117:399–406.
33. van Wolfswinkel ME, Zwart JJ, Schutte JM, Duvekot JJ, Pel M, van Roosmalen J. Maternal mortality and serious maternal morbidity in Jehovah’s witnesses in the Netherlands. BJOG. 2009;116(8):1103–8.
34. Zwart JJ, Yazdani ST, Harvey MS, de Vries RRP, van Roosmalen J. Underreporting of major obstetric haemorrhage in the Netherlands. Transfus Med. 2010;20(2):118–22.
35. Knight M. The International Network of Obstetric Survey Systems (INOSS): benefits of multi-country studies of severe and uncommon maternal morbidities. Acta Obstet Gynecol Scand. 2014;93(2):127–31.